We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10,914.00 | 10,912.00 | 10,916.00 | 10,934.00 | 10,764.00 | 10,914.00 | 557,038 | 15:36:01 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.43 | 169.31B |
From Apr 2019 to Apr 2024
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Tuesday that it is discontinuing global clinical trials for lanabecestat, a treatment for Alzheimer's disease that the pharmaceutical company has been jointly developing with Eli Lilly & Co. (LLY).
The decision is based on recommendations from an independent data-monitoring committee that concluded lanabecestat was unlikely to meet primary endpoints in clinical trials in early and mild Alzheimer's disease, AstraZeneca said. The decision wasn't based on safety concerns, the company said.
AstraZeneca and Lilly announced an alliance in 2014 for the development and commercialization of lanabecestat, in which Lilly would lead clinical development and AstraZeneca would be responsible for manufacturing.
Write to Adria Calatayud at adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
June 12, 2018 02:36 ET (06:36 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
